Protection against Radiation-Induced Carcinogenesis

我们已经完成了一项研究，探索肠道微生物区系对 辐射致癌动物的肠道菌群组成通过使用 抗生素鸡尾酒在饮用水之前全身辐射。我们发现 全身照射（TBI）前3周减少肠道菌群，缩短照射后3周 与单独的TBI相比，小鼠的寿命延长，暗示肠道微生物群落的重要性 在辐射诱发的致癌作用中。我们对暴露在空气中的老鼠的寿命研究接近尾声 非致死性的3戈伊TBI，食物中有和没有雷帕霉素。初步数据显示， 与单独TBI相比，雷帕霉素治疗通过降低小鼠的死亡率延长了小鼠的寿命。 诱发肝细胞癌。该研究将于2022年秋季完成。以来 雷帕霉素是FDA批准用于人类的，它提供的保护，辐射诱导 致癌作用使其成为暴露于非致死性TBI的人类的合理候选物。

We have finished a study exploring the influence of the gut microflora on radiation-induced carcinogenesis. The animal's gut microflora composition was modulated by use of an antibiotic cocktail in the drinking water prior to whole body radiation. We found that reducing the gut microflora 3 weeks before total body radiation (TBI) 3 weeks after shortened the lifespan of mice compared to TBI alone, implicating the importance of the gut microflora in radiation-induced carcinogenesis. We are near the end of a life span study in mice exposed to non-lethal 3 Gy TBI with and without rapamycin in their chow. Preliminary data show that rapamycin treatment extended the life span of mice compared to TBI alone by decreasing the induction of hepatocellular carcinomas. The study will be completed by the fall of 2022. Since rapamycin is FDA approved for use in humans, the protection it provides to radiation-induced carcinogenesis makes it a reasonable candidate for humans exposed to non-lethal TBI.